ChromaCode this week launched its first product, a research-use-only test for nine tick-borne pathogens designed for research use on any thermal cycler.
The researchers are using mass spectrometry to look in patient blood samples for peptides shed by Borrelia burgdorferi, the bacteria that causes Lyme disease.
Using more than 16,000 tick samples submitted by individuals in the mainland US and Puerto Rico, researchers documented tick species and infection by four pathogens.
The CDC says that the number of people in the US who have been infected with diseases carried by mosquitoes, ticks, and flea bites have more than tripled in recent years.
Investigators retraced features contributing to Lyme disease spread by sequencing 146 Borrelia burgdorferi isolates collected in North America since the 1980s.
Researchers used mass spectrometry to identify unique biochemical markers that differentiate Lyme disease from southern tick-associated rash Illness.
The firm remains on track to file for FDA clearance of its T2Bacteria panel, which its CEO called a "game changer" by mid-2017.
Crowdfunding will help move the targeted sequencing-based test through the development process in hopes of commercializing it.
The company said its product revenues rose during the fourth quarter thanks to an increase in T2Candida panel sales due to increased patient testing.
The funds, which the company said are part of a larger $9 million Series A round, will support the development of its test for early diagnosis of Lyme disease.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.